Connect Biopharma Holdings Ltd CNTB

About Connect Biopharma Holdings Ltd (CNTB): stock profile, AI score and financials

Connect Biopharma Holdings Ltd (CNTB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CNTB at 6.6/100 on a composite quality score built from its SEC filings, placing it at rank #2,913 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Connect Biopharma Holdings Ltd reports quarterly revenue of $2.8M, net income of $-17.3M, free cash flow of $-15.9M. Top institutional holders of CNTB by reported 13-F value include Ikarian Capital, 683 Capital Management, BOOTHBAY FUND MANAGEMENT, based on the most recent SEC filings. CNTB trades on the Nasdaq exchange and files with the SEC under CIK 1835268. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CNTB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Connect Biopharma Holdings Ltd directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1835268 →